Results 101 to 110 of about 50,237 (216)

Emerging Role of Cetuximab in the Treatment of Colorectal Cancer

, 2012
CRC is the fourth most frequently diagnosed tumor and the second leading cause of cancer death in the United States. KRAS mutations occur in 35-45% of metastatic-CRC and preclude responsiveness to cetuximab or panitumumab.
ROSSI, Luigi, GIORDANI, ERIKA, SPINELLI, GIAN PAOLO, Angelo Zullo, LO RUSSO, GIUSEPPE, PETROZZA, Vincenzo, PAPA, ANSELMO, TOMAO, SILVERIO   +7 more
core   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Pharmacogenomics of cetuximab in metastatic colorectal cancer.

, 2014
Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to ...
Russo, A., Giampieri, R., FALCONE, ALFREDO, Santini, D., Tonini, G., LOUPAKIS, FOTIOS, Vincenzi, B., Lorusso, V., Scartozzi, M., Silvestris, N., Cascinu, S., Brunetti, A. E., Dell'Aquila, E.   +12 more
core  

The biological properties of cetuximab

, 2008
Cetuximab is a recombinant chimeric human murine immunoglobulin G1 antibody that binds to the extra-cellular domain of epidermal growth factor receptor with a higher affinity than either endogenous ligand.
Schiavon G, Santini D, Vincenzi B, Silletta M, Tonini G   +4 more
core   +1 more source

Biomarkers Predictive of Immunotherapy Efficacy in Head and Neck Squamous Cell Carcinoma: Current Insights and Future Perspectives

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT With the approval of immunotherapies by regulatory bodies, head and neck squamous cell carcinoma (HNSCC) treatment has been revolutionized, and anti‐programmed cell death‐1 (anti‐PD‐1) agents are now the standard for platinum‐resistant recurrent/metastatic HNSCC.
Xiao‐Tong Yan, Zhao‐Hong An, Chang‐Ming An   +2 more
wiley   +1 more source

Current Advances of Treatments, Therapeutic Targets, Biomarkers, Novel Drugs, and Machine Learning for Hypopharyngeal Squamous Cell Carcinoma

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Hypopharyngeal squamous cell carcinoma (HSCC) is an aggressive subtype of head and neck squamous cell carcinoma with insidious onset, early metastasis, and dismal prognosis. Conventional multimodal therapy achieves limited survival benefit, highlighting an urgent need for refined precision strategies.
Ce Li, Rui Guan, Rui‐Jie Jiao, Zhi‐Jie Bi, Yang Fu, Yin Wang, Chen‐Yang Xu, Ye Qian, Ran Wei, Sheng‐Da Cao, Wen‐Ming Li, Dong‐Min Wei, Da‐Peng Lei   +12 more
wiley   +1 more source

Benchmarked Colorectal Cancer Outcomes in a Metropolitan Hospital: A 5‐Year Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
In metastatic disease, patients with lung‐only metastasis had the best 5‐year survival at 46.0% and curative‐intent approaches can dramatically improve survival. ABSTRACT Introduction Colorectal cancer (CRC) remains a major contributor to cancer‐related mortality worldwide, with survival influenced by many prognostic factors.
Jialin Du, Vincent Wang, Basil D'Souza, Russell Hodgson   +3 more
wiley   +1 more source

Cetuximab and paclitaxel combination therapy for recurrent basaloid squamous cell carcinoma in the ethmoid sinus [PDF]

Basaloid squamous cell carcinoma (BSCC), a histologically distinctive variant of squamous cell carcinoma comprising basal cell carcinoma and squamous cell carcinoma, is aggressive and shows a poor prognosis because of frequent lymph node invasion and ...
藤原, 和典, Nakamura, Yosuke, 福原, 隆宏, フクハラ, タカヒロ, フジワラ, カズノリ, 小山, 哲史, コヤマ, サトシ, 2504, Morisaki, Tsuyoshi, 100002206, Koyama, Satoshi, 70403417, 3674, 80403418, 40197273, 90403419, 100001318, 4942, Fujiwara, Kazunori, Fukuhara, Takahiro, Takeuchi, Hiromi, ナカムラ, ヨウスケ, タケウチ, ヒロミ, 竹内, 裕美, 100000179, 369, 中村, 陽祐, 405, 100001307, 100000417, Fujii, Taihei, 26281, 26280   +32 more
core  

Nimotuzumab Combined With Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma: A Systematic Review and Meta‐Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This meta‐analysis of 18 studies (3962 patients) demonstrates that nimotuzumab combined with chemoradiotherapy significantly improves overall survival and progression‐free survival in locally advanced head and neck squamous cell carcinoma, without increasing severe toxicity.
Chengzheng Bao, Yue Zhang, Xiang Fei, Kaifeng Ji, Ming Jia, Zhijun Li, Chao Bian   +6 more
wiley   +1 more source

Berberine: a promising strategy to combat cetuximab-resistance in colorectal cancer

BMC Cancer
Cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), is approved as a front-line treatment for metastatic colorectal cancers, but limited efficacy is obtained.
Jianmin Ye, Bingchan Sun, Fengmei Xia, Guoxin Wang, Huimin Liu, Jianghua Ding, Mingfu Tong   +6 more
doaj   +1 more source